GSK1144814

GSK1144814 is a small molecule dual antagonist of the neurokinin-1 (NK1) and neurokinin-3 (NK3) receptors, developed by GSK. It was designed to target the tachykinin system, which plays a significant role in the pathophysiology of various psychiatric and neurological disorders. By blocking NK1 and NK3 receptors, the compound aimed to modulate the release of neurotransmitters like dopamine and serotonin, potentially offering therapeutic benefits for schizophrenia, depression, and drug addiction. Clinical development reached Phase 1, including studies evaluating its safety, pharmacokinetics, and potential interactions with alcohol to assess psychomotor and cognitive effects. The compound appears to have been a research candidate that did not progress into late-stage clinical development.